Aclarubicin (aclacinomycin A) and irradiation: evaluation using HeLa cells.
Aclarubicin (aclacinomycin A), an anthracyclic anti-tumor antibiotic, was examined as a possible factor to improve survival of proliferating HeLa cells following irradiation. After irradiation followed by exposure to 5 micrograms/ml of aclarubicin for 1 hour, cell killing was significantly enhanced from 2 hours onward, reaching a maximum at 24 hours. The maximum enhancement ratio, determined from comparison of D0 values (mean lethal radiation doses), was 2.3. Aclarubicin did not potentiate cell killing appreciably when it was given prior to or simultaneously with irradiation. Potentiation cannot be attributed to suppression of recovery from sublethal radiation damage, but rather is due to interaction between radiation and drug damage and lasts through approximately 10 divisions. A recall effect may be predicted on the basis of these findings.
D015250:Aclarubicin; D000903:Antibiotics, Antineoplastic / Q000494:pharmacology*; D002470:Cell Survival; D006367:HeLa Cells; D006801:Humans; D066298:In Vitro Techniques; D009279:Naphthacenes / Q000494:pharmacology; D011829:Radiation Dosage; D011838:Radiation-Sensitizing Agents
D000903:Antibiotics, Antineoplastic; D009279:Naphthacenes; D011838:Radiation-Sensitizing Agents; D015250:Aclarubicin